Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection

Chung- Er Huang's Biography

Chung- Er Huang, Assistant Professor, National Chiao Tung University; Managing Director, CytoAurora Biotechnologies, Inc.

Dr. Chung-Er Huang received his Ph.D degree from the Electron Institute, National Chiao-Tung University, Hsinchu, Taiwan. From 1999 to 2000, he was with the Global Communication Semiconductors Inc., USA. From 2000 to 2004, he served as a director in Win Semiconductors Corp., Taiwan. From 2004 to 2005, he served as a senior director in Etron Technology Inc., Taiwan. From 2005, he joined AzureWave Technologies, Inc., Taiwan, and served as the Vice President of Business Unit Head until 2015. He possesses a comprehensive knowledge and experiences in semiconductor and electrical technologies. In 2015, he founded Cytoaurora Biotehnologies, Inc. in Jhubei City, Taiwan, as a CEO aiming to develop novel biomedical technologies based on advanced semiconductor sciences. Research interests of Dr. Huang encompass high-speed semiconductors devices, designs, RF circuit and SiP (System-in-Package) implementations, and development of nanostructure materials and microfluidic platforms for molecular diagnostics and therapeutics. He owns over 55 patents related to Biotechnologies, high-speed semiconductor, wireless processes, design and assembly. Dr. Huang’s current primary focus is on the development of a novel nano-system for capturing Circulating Rare Cells based on advanced technologies.

Chung- Er Huang Image

Application of Artificial Intelligence and Semiconductor Technologies in Liquid Biopsy

Thursday, 29 March 2018 at 17:30

Add to Calendar ▼2018-03-29 17:30:002018-03-29 18:30:00Europe/LondonApplication of Artificial Intelligence and Semiconductor Technologies in Liquid

The demand for basic research and commercial applications of liquid biopsy has increased along with the need for reliable automation to promote the market growth. In this presentation, we will introduce a novel system (“Cell Reveal”) for rare cells captured. The novel system in capturing rare cells (CTC/CFC) has been robustly developed based on an advanced technology which integrates semiconductor manufacturing technology, biotechnology, automation, and artificial intelligence.  The system (“Cell Reveal”) consists of cell-capture, cell-analysis, enumeration, and cell separation.  The capture of rare cells is performed by a combination of a bio-chip and microfluidics as the cells flow through the surface of the biochip.  The high capture rate of the bio-chip is achieved by a similar dimensional nano-structure in a high-density arrangement. Enumeration of rare cells can be accomplished by the Cell Analysis Tool, which also provides molecular analysis and genetic makeup of the target cells as well as their locations on the chip. The intact cells are subjected to separation, resulting in individual target cells collected for subsequent single Whole Genome Amplification (WGA) and WGS.  This novel nano-system greatly improves and accelerates patients' diagnostics and therapeutics.

Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection